Back to Newsroom
Back to Newsroom

RDInvesting Provides Investors with Free In-Depth Equity Reports on BIOS, DYAX, NKTR and OGXI

Friday, 28 February 2014 08:40 AM

Topic:

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

BioScrip Inc. (NASDAQ: BIOS) shares dropped 12.32 percent to close at $7.40 a share Thursday. The stock traded between $7.33 and $8.18 on volume of 8.21 million shares traded. Analysts at Sidoti have recently downgraded the company’s rating to “neutral” from “buy”. Shares of BioScrip have fallen approximately 35.0 percent in the past year.

Find out more about BioScrip including full access to the free equity report at:       
www.RDInvesting.com/BIOS

Dyax Corp. (NASDAQ: DYAX) shares declined 5.73 percent to close at $10.20 a share Thursday. The stock traded between $9.65 and $10.47 on volume of 1.86 million shares traded. Analysts at Leerink have recently downgraded the company’s rating to “market perform” from “outperform”. Shares of Dyax have gained approximately 35.0 percent year-to-date.

Find out more about Dyax including full access to the free equity report at:       
www.RDInvesting.com/DYAX

Nektar Therapeutics (NASDAQ: NKTR) shares declined 4.67 percent to close at $13.06 a share Thursday. The stock traded between $12.38 and $13.40 on volume of 2.45 million shares traded. Analysts at MKM Partners have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Nektar Therapeutics have gained approximately 15.0 percent year-to-date.

Find out more about Nektar Therapeutics including full access to the free equity report at:     
www.RDInvesting.com/NKTR

OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI) shares gained 1.65 percent to close at $11.70 a share Thursday. The stock traded between $11.56 and $11.85 on volume of 379,943 shares traded. Analysts at CRT Capital have recently initiated coverage on the company with a “buy” rating and a price target of $20.00. Shares of OncoGenex Pharmaceuticals have gained approximately 40.0 percent year-to-date.

Find out more about OncoGenex Pharmaceuticals including full access to the free equity report at:        
www.RDInvesting.com/OGXI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:                   
Research Driven Investing           
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: